MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS

被引：0

作者：

Wild, L. ^{[1
]}

Forster, L. ^{[1
]}

机构：

[1] Double Helix Consulting, London, England

来源：

VALUE IN HEALTH | 2011年 / 14卷 / 07期

关键词：

D O I：

10.1016/j.jval.2011.08.566

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A335 / A336

页数：2

共 50 条

[1] Pricing and reimbursement of orphan drugs in Italy
Lopatriello, S.
Schivazappa, C.
Negrini, C.
Berto, P.
VALUE IN HEALTH, 2006, 9 (06) : A208 - A209
[2] PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN CANADA
Kumar, J.
Bachman, E. M.
VALUE IN HEALTH, 2011, 14 (03) : A29 - A29
[3] REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN
Cheng, C. Y.
Chan, H. W.
Fang, C. H.
VALUE IN HEALTH, 2019, 22 : S856 - S856
[4] Orphan drugs: pricing, reimbursement and patient access
Barak, Adam
Nandi, Jyoti Shankar
INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
[5] Pricing and reimbursement of orphan drugs: the need for more transparency
Steven Simoens
Orphanet Journal of Rare Diseases, 6
[6] Pricing and reimbursement of orphan drugs: the need for more transparency
Simoens, Steven
ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
[7] Orphan Drug Pricing and Reimbursement Policies Lacking in EU
不详
PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 297 - 298
[8] PRICING AND REIMBURSEMENT SYSTEM OF ORPHAN DRUGS IN THE CZECH REPUBLIC
Prochazkova, M.
Kubickova, P.
Mazelova, J.
Hambalek, J.
Heislerova, M.
VALUE IN HEALTH, 2013, 16 (07) : A474 - A474
[9] INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS
Rousseau, B.
Poinas, A.
Oliver, L.
Collings, H.
VALUE IN HEALTH, 2017, 20 (09) : A695 - A696
[10] INDICATION-SPECIFIC PRICING: HOW DO PAYERS MANAGE DRUGS WITH MULTIPLE INDICATIONS?
Gaba, D.
Patel, D.
Shah, S.
VALUE IN HEALTH, 2019, 22 : S301 - S301

← 1 2 3 4 5 →